Skip to main content
Androgen dynamics and serum PSA in patients treated with abiraterone acetate
Published Web Location
http://europepmc.org/articles/PMC4020277?pdf=renderNo data is associated with this publication.
Abstract
Background: We analyzed the potential of abiraterone acetate (henceforth abiraterone) to reduce androgen levels below lower limits of quantification (LLOQ) and explored the association with changes in PSA decline in metastatic castration-resistant prostate
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.